N. Nicole Endejann

Let me gather details on the tracked cases and IPR proceedings.

Let me verify her firm history, PTAB activity, and any other reported matters.

N. Nicole Endejann — patent litigation summary

Focus areas. Ms. Endejann's practice is life-sciences and pharmaceutical patent work rather than electronics or standards-essential litigation. Her DLA Piper profile describes strategic patent prosecution and counseling, product-exclusivity strategies, trade-secret protection, and IP due diligence in pharmaceutical, biologic, medical device, nutraceutical, and cosmetic fields, with a specific emphasis on the interplay of FDA regulatory exclusivity and patent law (Orange Book listing, patent term extension). Chambers USA (2026) ranks her in Intellectual Property – Pennsylvania (Band 4) for strategic IP counsel, patent prosecution, and transactional due diligence. The tracked litigation is consistent with that profile: all four matters arise from a single Hatch-Waxman dispute over Neurelis's Valtoco (diazepam nasal spray) patents — non-aqueous intranasal benzodiazepine formulations — not from software, mechanical, or Wi-Fi/SEP subject matter. Nothing in the record indicates a broader commercial-litigation or tech-sector docket.

Side preference. She works the patent-owner side. The structured counts (3 defendant-side, 1 plaintiff-side) resolve to one client, Neurelis, Inc., the NDA holder and patent owner: DLA Piper represents Neurelis as plaintiff in the Delaware ANDA actions and, in the parallel PTAB petitions captioned Padagis US LLC v. Neurelis, Inc., as patent owner/responding party — which is how the docket data labels her as "defendant" side in three entries. There is no indication of NPE/PAE plaintiff-side prosecution or of regular representation of generic challengers.

Firm context. She is a partner in DLA Piper's Intellectual Property and Technology practice and Life Sciences sector, resident in Philadelphia, and joined in January 2022 from Troutman Pepper Hamilton Sanders as part of a three-partner IP group (with Raymond Miller and Joseph Helmsen) that had worked together for roughly two decades. Her earlier partnership was at Pepper Hamilton (Pittsburgh), which merged into Troutman Pepper in 2020. She has been a registered patent attorney since 2002; professional listings show her as first admitted in Ohio (2003 per Martindale) with current admissions in Ohio, Pennsylvania, New Jersey, and the USPTO, and admission to the U.S. District Court for the Northern District of Ohio. Education: Ohio Northern University, B.S. in pharmacy (1999, high distinction) and University of Akron School of Law, J.D. (2002, magna cum laude) — the pharmacy background aligns with her chemistry/formulation practice.

Notable matters and PTAB experience. Her most prominent tracked matter is the consolidated Delaware litigation Neurelis, Inc. v. Padagis LLC et al. (D. Del., lead C.A. No. 24-562-MN, Judge Maryellen Noreika), asserting Orange Book patents (including U.S. 8,895,546; 11,241,414; 11,793,786) against Padagis's ANDA No. 219320 for generic Valtoco. She appears in a support role (local/patent counsel and back-up counsel). The consolidated case is scheduled for a bench trial on March 1, 2027, with a Markman hearing in July 2026; no verdict, injunction, or settlement has been reported as of today. She is also back-up counsel for Neurelis (PTAB Reg. No. 50,229) in the three related instituted IPRs filed by Padagis — IPR2025-00464, -465, and -466 — where the Board has scheduled final written decisions around September 17, 2026. Those proceedings produced a notable administrative ruling: the Acting Director's decision declining discretionary denial (finding the examiner's priority determination contradicted PTAB's earlier holding in IPR2019-00451 on related U.S. 9,763,876) was designated informative on January 9, 2026; the Board separately denied Patent Owner's motion for leave to seek a certificate of correction (February 2026) and denied rehearing (March 20, 2026). Her PTAB activity is thus real but recent and clustered in this one patent family; I found no evidence of a broader, recurring IPR/PGR docket, and no reported trial verdicts or Federal Circuit arguments attributable to her.

Sources: DLA Piper firm profile and January 2022 lateral-hire announcement; Chambers USA 2026 profile; Legal 500 and Martindale profiles; PTAB filings and decisions in IPR2025-00464/-465/-466; D. Del. dockets via Justia/CourtListener. Practice-area facts beyond these sources (e.g., total litigation track record) are not independently verifiable from public records.